Related Experiment Video

Updated: May 23, 2026

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats
08:56

Estrogen-Like Effect of Bazi Bushen Capsule in Ovariectomized Rats

Published on: April 7, 2023

(-)-Epigallocathechin-3-gallate, an AMPK activator, decreases ovariectomy-induced bone loss by suppression of bone

Seung Hun Lee1, Beom-Jun Kim, Hyung Jin Choi

  • 1Division of Endocrinology and Metabolism, Asan Medical Center, College of Medicine, University of Ulsan, Songpa-Gu, Seoul, Republic of Korea.

Calcified Tissue International
|March 22, 2012
PubMed

Insights

(-)-Epigallocatechin-3-gallate (EGCG) prevents bone loss in ovariectomized mice by activating AMP-activated protein kinase (AMPK). EGCG treatment reduced osteoclast formation, preserving bone mineral density and structure.

Area of Science:

  • Biomedical Science
  • Bone Biology
  • Pharmacology

Background:

  • AMP-activated protein kinase (AMPK) is known to negatively regulate osteoclast formation.
  • Ovariectomy (OVX) in mice is a common model for studying postmenopausal bone loss.
  • (-)-Epigallocatechin-3-gallate (EGCG) is a natural compound that activates AMPK.

Purpose of the Study:

  • To investigate the therapeutic potential of EGCG in preventing ovariectomy-induced bone loss.
  • To elucidate the mechanism by which EGCG affects bone metabolism in vivo.
  • To assess the role of AMPK activation in EGCG's bone-protective effects.

Main Methods:

  • Ovariectomy (OVX) was performed on female mice, followed by 8 weeks of EGCG administration.
  • Bone mineral density (BMD) was measured using dual-energy X-ray absorptiometry.
  • Micro-computed tomography (micro-CT) and bone histomorphometry were used to analyze bone structure and osteoclast parameters.
  • Western blot analysis detected AMPK activation in bone tissue.

Main Results:

  • EGCG administration prevented OVX-induced body weight gain and attenuated bone loss.
  • Micro-CT analysis showed EGCG increased trabecular bone volume and number, while decreasing spacing.
  • Histomorphometry revealed that EGCG suppressed osteoclast surface and number.
  • EGCG treatment significantly increased phosphorylated AMPK levels in bone.

Conclusions:

  • EGCG effectively mitigates ovariectomy-induced bone loss in mice.
  • The bone-protective effects of EGCG are mediated through the inhibition of osteoclast formation.
  • EGCG's mechanism involves the activation of the AMPK pathway in bone tissue.

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...